Veligrotug：首次批准。
完整摘要 · 中文译文
Veligrotug (veligrotug-vvze; LUMVOA™) 是一种单克隆抗体胰岛素样生长因子-1受体（IGF-1R）抑制剂，由Viridian Therapeutics开发，用于治疗甲状腺眼病（也称为Graves眼病/眼眶病或甲状腺相关性眼病）。2026年6月，基于两项多国III期临床试验的阳性结果，veligrotug获美国FDA批准用于治疗甲状腺眼病，无论疾病活动性或病程如何。本文总结了veligrotug在开发中促成其首次获批治疗甲状腺眼病的里程碑事件。
完整摘要 · 英文原文
Veligrotug (veligrotug-vvze; LUMVOA™) is a monoclonal antibody insulin-like growth factor-1 receptor (IGF-1R) inhibitor that was developed by Viridian Therapeutics for the treatment of thyroid eye disease (also known as Graves ophthalmopathy/orbitopathy or thyroid-associated ophthalmopathy). In June 2026, veligrotug was approved by the US FDA for the treatment of thyroid eye disease regardless of disease activity or duration, based on positive results from two multinational phase III clinical trials. This article summarizes the milestones in the development of veligrotug leading to this first approval for thyroid eye disease.